Table 3.
New onset of diabetes‐related endpoints in JADE and DIAMOND study groups
| n | DIAMOND, n (%) | n | JADE, n (%) | |
|---|---|---|---|---|
| All patients with vitality status | 1549 | 1646 | ||
| Self‐reported new cardiovascular event (coronary heart disease or stroke) | 30 (1.9) | 42 (2.5) | ||
| Returnees | 1176 | 21 (1.8) | 1383 | 27 (2.0) |
| Non‐returnees | 373 | 9 (2.4) | 263 | 15 (5.7) |
| Death | 6 (0.3) | 6 (0.18) | ||
| Returnees for repeat assessment | 1176 | 1383 | ||
| New chronic kidney disease: 50% loss of estimated GFR | 900 | 16 (1.8) | 1026 | 12 (1.2) |
| New appearance of sensory neuropathy in patients without sensory neuropathy at baseline | 1072 | 49 (4.6) | 1048 | 52 (5.0) |
| Remission of sensory neuropathy in patients with sensory neuropathy at baseline | 96 | 70 (72.9) | 75 | 53 (70.7) |
| Worsening or new appearance of diabetic retinopathy | 992 | 28 (2.8) | 869 | 37 (4.3) |
| Improvement of diabetic retinopathy in patients with diabetic retinopathy at baseline | 59 | 59 (100) | 45 | 41 (91.1) |
| Improved visual acuity in at least one eye | 563 | 164 (29.1) | 657 | 228 (34.7) |
| Deteriorated visual acuity in at least one eye | 570 | 216 (37.9) | 658 | 239 (36.3) |
DIAMOND, DIAbetes MONitoring Database; JADE, Joint Asia Diabetes Evaluation.
Worsening /improvement of diabetic retinopathy is defined as advancement or stabilization in the grading by ophthalmologist (pre‐proliferative, proliferative, advanced).
n includes returnees and a subset of defaulters who could be reached for health status assessment at study end.